BioMarin Pharmaceutical Inc. (BMRN) Financial Ratios
28 years of historical data (1998–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
16.04
↓-90% vs avg
5yr avg: 165.72
30Y Low18.0·High75.8
P/FCF
↓
14.48
↓-91% vs avg
5yr avg: 156.35
30Y Low16.2·High87.2
P/B Ratio
↓
1.77
↓-45% vs avg
5yr avg: 3.20
30Y Low1.9·High18.1
ROE
↑
5.9%
↓+55% vs avg
5yr avg: 3.8%
30Y Low-141%·High40%
Debt/EBITDA
↓
1.05
↓-90% vs avg
5yr avg: 10.50
30Y Low1.0·High42.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BMRN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioMarin Pharmaceutical Inc. trades at 30.3x earnings, 61% below its 5-year average of 77.6x, sitting at the 43rd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 37%. On a free-cash-flow basis, the stock trades at 14.5x P/FCF, 91% below the 5-year average of 156.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.5B | $11.7B | $12.9B | $18.5B | $19.6B | $16.2B | $16.8B | $15.1B | $15.1B | $15.6B | $13.8B |
| Enterprise Value | $9.8B | $11.1B | $12.6B | $18.8B | $19.9B | $16.7B | $17.2B | $15.6B | $15.4B | $16.1B | $14.0B |
| P/E Ratio → | 30.33 | 33.02 | 29.74 | 109.57 | 137.99 | — | 19.36 | — | — | — | — |
| P/S Ratio | 3.26 | 3.64 | 4.53 | 7.64 | 9.33 | 8.75 | 9.03 | 8.88 | 10.12 | 11.84 | 12.33 |
| P/B Ratio | 1.77 | 1.93 | 2.29 | 3.73 | 4.25 | 3.79 | 4.09 | 4.85 | 5.09 | 5.54 | 4.98 |
| P/FCF | 14.48 | 16.18 | 27.20 | 295.26 | 355.93 | 87.18 | — | — | — | — | — |
| P/OCF | 12.68 | 14.17 | 22.57 | 116.00 | 111.17 | 53.05 | 196.90 | 313.66 | 746.95 | — | — |
P/E links to full P/E history page with 30-year chart
BMRN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
BioMarin Pharmaceutical Inc.'s enterprise value stands at 16.0x EBITDA, 90% below its 5-year average of 165.7x. The Healthcare sector median is 14.1x, placing the stock at a 13% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.43 | 4.43 | 7.78 | 9.51 | 9.02 | 9.27 | 9.13 | 10.35 | 12.28 | 12.58 |
| EV / EBITDA | 16.04 | 18.05 | 21.76 | 64.84 | 75.78 | 648.19 | 279.37 | 3212.70 | — | 220.47 | — |
| EV / EBIT | 18.43 | 22.42 | 22.80 | 92.96 | 121.95 | — | — | — | — | 5191.53 | — |
| EV / FCF | — | 15.26 | 26.58 | 300.70 | 362.64 | 89.89 | — | — | — | — | — |
BMRN Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioMarin Pharmaceutical Inc. earns an operating margin of 16.6%. Operating margins have expanded from 7.7% to 16.6% over the past 3 years, signaling improving operational efficiency. ROE of 5.9% is modest. ROIC of 7.4% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.1% | 77.1% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% |
| Operating Margin | 16.6% | 16.6% | 17.0% | 7.7% | 7.7% | -4.5% | -2.3% | -5.9% | -8.3% | -1.1% | -71.9% |
| Net Profit Margin | 10.8% | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.9% | 5.9% | 8.0% | 3.5% | 3.2% | -1.5% | 23.6% | -0.8% | -2.7% | -4.2% | -24.4% |
| ROA | 4.8% | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.2% | -0.5% | -1.7% | -2.7% | -16.3% |
| ROIC | 7.4% | 7.4% | 6.8% | 2.7% | 2.5% | -1.3% | -0.8% | -2.2% | -2.8% | -0.3% | -21.1% |
| ROCE | 8.1% | 8.1% | 8.0% | 3.2% | 2.9% | -1.5% | -1.0% | -2.6% | -3.2% | -0.4% | -23.4% |
BMRN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
BioMarin Pharmaceutical Inc. carries a Debt/EBITDA ratio of 1.0x, which is manageable (68% below the sector average of 3.3x). The company holds a net cash position — cash of $1.3B exceeds total debt of $643M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 45.3x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.11 | 0.22 | 0.24 | 0.26 | 0.26 | 0.28 | 0.28 | 0.42 | 0.25 |
| Debt / EBITDA | 1.05 | 1.05 | 1.12 | 3.78 | 4.16 | 42.40 | 17.61 | 177.33 | — | 16.05 | — |
| Net Debt / Equity | — | -0.11 | -0.05 | 0.07 | 0.08 | 0.12 | 0.11 | 0.13 | 0.11 | 0.21 | 0.10 |
| Net Debt / EBITDA | -1.09 | -1.09 | -0.51 | 1.17 | 1.40 | 19.54 | 7.09 | 87.01 | — | 7.88 | — |
| Debt / FCF | — | -0.92 | -0.62 | 5.44 | 6.71 | 2.71 | — | — | — | — | — |
| Interest Coverage | 45.27 | 45.27 | 43.75 | 11.68 | 10.23 | -3.95 | -0.73 | -3.13 | -2.27 | 0.07 | -20.13 |
Net cash position: cash ($1.3B) exceeds total debt ($643M)
BMRN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BioMarin Pharmaceutical Inc.'s current ratio of 5.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.50x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.51x to 5.21x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.21 | 5.21 | 5.33 | 2.51 | 4.67 | 4.16 | 4.76 | 2.08 | 3.93 | 2.70 | 3.24 |
| Quick Ratio | 3.50 | 3.50 | 3.29 | 1.57 | 3.15 | 2.74 | 3.34 | 1.35 | 2.92 | 2.12 | 2.43 |
| Cash Ratio | 2.06 | 2.06 | 1.87 | 0.91 | 2.19 | 1.86 | 2.16 | 0.81 | 2.07 | 1.71 | 1.80 |
| Asset Turnover | — | 0.42 | 0.41 | 0.35 | 0.33 | 0.31 | 0.32 | 0.36 | 0.34 | 0.28 | 0.28 |
| Inventory Turnover | 0.57 | 0.57 | 0.47 | 0.48 | 0.56 | 0.61 | 0.75 | 0.53 | 0.59 | 0.51 | 0.59 |
| Days Sales Outstanding | — | 102.91 | 84.48 | 95.61 | 80.33 | 73.82 | 87.96 | 80.84 | 83.86 | 72.62 | 70.36 |
BMRN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioMarin Pharmaceutical Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 3.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.3% | 3.0% | 3.4% | 0.9% | 0.7% | — | 5.2% | — | — | — | — |
| FCF Yield | 6.9% | 6.2% | 3.7% | 0.3% | 0.3% | 1.1% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.2% | 0.2% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.2% | 0.2% | 0.0% |
| Shares Outstanding | — | $197M | $197M | $192M | $189M | $183M | $192M | $179M | $177M | $174M | $166M |
Peer Comparison
Compare BMRN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BMRNYou | $11B | 30.3 | 16.0 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 SRPT | $2B | -3.2 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 RCKT | $418M | -1.9 | — | — | — | — | -60.3% | -63.2% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 28 years · Updated daily
Full BMRN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BMRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMRN vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonBMRN — Frequently Asked Questions
Quick answers to the most common questions about buying BMRN stock.
What is BioMarin Pharmaceutical Inc.'s P/E ratio?
BioMarin Pharmaceutical Inc.'s current P/E ratio is 30.3x. The historical average is 58.1x. This places it at the 43th percentile of its historical range.
What is BioMarin Pharmaceutical Inc.'s EV/EBITDA?
BioMarin Pharmaceutical Inc.'s current EV/EBITDA is 16.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 46.5x.
What is BioMarin Pharmaceutical Inc.'s ROE?
BioMarin Pharmaceutical Inc.'s return on equity (ROE) is 5.9%. The historical average is -17.7%.
Is BMRN stock overvalued?
Based on historical data, BioMarin Pharmaceutical Inc. is trading at a P/E of 30.3x. This is at the 43th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BioMarin Pharmaceutical Inc.'s profit margins?
BioMarin Pharmaceutical Inc. has 77.1% gross margin and 16.6% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does BioMarin Pharmaceutical Inc. have?
BioMarin Pharmaceutical Inc.'s Debt/EBITDA ratio is 1.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.